Back to News
Market Impact: 0.25
AbbVie's Subcutaneous Skyrizi Shows Endoscopic Benefits In Crohn's Diseases
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
AbbVie reported new Phase 3 AFFIRM data on endoscopic outcomes with subcutaneous Skyrizi in adults with moderately to severely active Crohn’s disease. The report provides no numerical results or further detail on the outcomes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
ABBV0.45
More News
- Cue Biopharma VP Meluzio sells $32,089 in Cue stock for tax
- Anthropic's third-quarter revenue is said to hit $16.8 billion ahead of IPO
- SK Hynix seeks U.S. chip equipment exports to China tied to new factory
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- Why is Netwealth stock sliding today?
- Bending Spoons skyrockets 35% as Berkshire Hathaway makes $330 million investment